Hyperkalemia Market Hots Up In EU with Okay for AZ's Lokelma

 
• By Kevin Grogan

Rival Vifor Pharma has predicted blockbuster status for Veltassa and AstraZeneca expects the same for its just-approved oral potassium-removing agent, hoping that Lokelma's faster onset of action will help it win the fight for market share in hyperkalemia.

Fire
Lokelma OK lights the fire for competition in hyperkalemia • Source: Shutterstock

More from New Products

More from Scrip